Skip to main content
Contact Us
Subscribe
E-Edition
71°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Atara Biotherapeutics, Inc.
< Previous
1
2
3
Next >
Atara Biotherapeutics Announces Plans to Submit Tab-cel® BLA in Q2 2024 Following FDA Agreement on Comparability
September 19, 2023
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
September 01, 2023
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics to Participate in Cell Therapies in Autoimmune Panel Discussion at the Citi 18th Annual BioPharma Conference
August 31, 2023
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics Announces Second Quarter 2023 Financial Results and Operational Progress
August 08, 2023
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 04, 2023
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics to Announce Second Quarter 2023 Financial Results on Tuesday, August 8, 2023
August 01, 2023
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics to Participate in the Canaccord Genuity 43rd Annual Growth Conference
July 31, 2023
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 07, 2023
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference
June 07, 2023
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics Presents Updated Tab-cel® Clinical Effectiveness Data at ASCO 2023
June 05, 2023
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 02, 2023
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics Announces First Quarter 2023 Financial Results and Operational Progress
May 08, 2023
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 05, 2023
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics to Announce First Quarter 2023 Financial Results on Monday, May 8, 2023
May 01, 2023
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 31, 2023
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 03, 2023
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 43rd Annual Health Care Conference
March 01, 2023
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics to Participate in the H.C. Wainwright Cell Therapy Virtual Conference
February 21, 2023
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Operational Progress
February 08, 2023
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Pierre Fabre to Commercialize and Distribute the First Approved Allogeneic T-cell Immunotherapy in Europe Following Transfer of the European Commission Marketing Authorization of EBVALLO™ (tabelecleucel)
February 08, 2023
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results on Wednesday, February 8, 2023
February 06, 2023
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 03, 2023
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 13, 2023
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 04, 2023
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics Announces $31 Million Royalty Interest Financing Agreement with HealthCare Royalty
December 20, 2022
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics Announces Changes to Its Board of Directors
December 19, 2022
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics’ Ebvallo™ (tabelecleucel) Receives European Commission Approval as First Ever Therapy for Adults and Children with EBV+ PTLD
December 19, 2022
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
December 15, 2022
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics Presents Updated Clinical Data from Pivotal Phase 3 Trial (ALLELE) of Tab-cel® at the 64th American Society of Hematology (ASH) Annual Meeting
December 12, 2022
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
December 02, 2022
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.